CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Everiondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04134429
NCT04134429N/ACompleted
CompareCT.gov

Continuous Monitoring of Health Data With a Wearable Device in Pediatric Patients Undergoing Chemotherapy for Cancer - a Feasibility Pilot Study

Insel Gruppe AG, University Hospital Bern·observational·Posted Oct 22, 2019·Updated Jul 8, 2021

In Brief

An observational study evaluating Everion for Pediatric Cancer and 3 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cancer, is studied. Feasibility is assessed by the number of patients wearing the device on seven consecutive days for at least 18h/day, what will be measured by monitored heart rate. Study duration for each participant is 14 days.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Cancer, Febrile Neutropenia, Chemotherapy-induced Neutropenia, Oncology
CountriesSwitzerland
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 22, 2019
Enrollment StartNov 29, 2019
Primary CompletionJan 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.7 years ago

Interventions

Everiondevice

The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.